{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:49:58Z","timestamp":1793321398533,"version":"4.5.0"},"reference-count":35,"publisher":"American Society of Hematology","issue":"24","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,12,12]]},"abstract":"<jats:p>In a Plenary Paper, Young et al describe impressive favorable outcomes of emicizumab prophylaxis in children with hemophilia A and factor VIII inhibitors, reporting a 99% reduction in annualized bleeding, with 77% of patients having no treated bleeding events.<\/jats:p>","DOI":"10.1182\/blood.2019001869","type":"journal-article","created":{"date-parts":[[2019,10,14]],"date-time":"2019-10-14T14:15:39Z","timestamp":1571062539000},"page":"2127-2138","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":375,"title":["A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors"],"prefix":"10.1182","volume":"134","author":[{"given":"Guy","family":"Young","sequence":"first","affiliation":[{"name":"Children\u2019s Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ri","family":"Liesner","sequence":"additional","affiliation":[{"name":"Great Ormond Street Hospital, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Chang","sequence":"additional","affiliation":[{"name":"Genentech, Inc, South San Francisco, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Robert","family":"Sidonio","sequence":"additional","affiliation":[{"name":"Children\u2019s Healthcare of Atlanta, Emory University, Atlanta, GA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1585-4100","authenticated-orcid":false,"given":"Johannes","family":"Oldenburg","sequence":"additional","affiliation":[{"name":"Institute of Experimental Hematology and Transfusion Medicine, University of Bonn, Bonn, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3937-3499","authenticated-orcid":false,"given":"Victor","family":"Jim\u00e9nez-Yuste","sequence":"additional","affiliation":[{"name":"Hospital Universitario La Paz, Aut\u00f3noma University, Madrid, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnny","family":"Mahlangu","sequence":"additional","affiliation":[{"name":"National Health Laboratory Service (NHLS), Charlotte Maxeke Johannesburg Academic Hospital, University of the Witwatersrand, Johannesburg, South Africa;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Kruse-Jarres","sequence":"additional","affiliation":[{"name":"Bloodworks Northwest, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9289-4862","authenticated-orcid":false,"given":"Michael","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Medicine Hemophilia and Thrombosis Center, Anschutz Medical Campus, University of Colorado, Aurora, CO;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Uguen","sequence":"additional","affiliation":[{"name":"F. Hoffmann\u2013La Roche Ltd, Basel, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle Y.","family":"Doral","sequence":"additional","affiliation":[{"name":"Genentech, Inc, South San Francisco, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilyan Y.","family":"Wright","sequence":"additional","affiliation":[{"name":"Genentech, Inc, South San Francisco, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Schmitt","sequence":"additional","affiliation":[{"name":"F. Hoffmann\u2013La Roche Ltd, Basel, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gallia G.","family":"Levy","sequence":"additional","affiliation":[{"name":"Genentech, Inc, South San Francisco, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Midori","family":"Shima","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Nara Medical University, Kashihara, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Elisa","family":"Mancuso","sequence":"additional","affiliation":[{"name":"Angelo Bianchi Bonomi Hemophilia and Thrombosis Centre, Ospedale Maggiore Policlinico, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ca\u2019 Granda, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2019121211523184300_B1","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/j.1365-2516.2012.02909.x","article-title":"Guidelines for the management of hemophilia","volume":"19","author":"Srivastava","year":"2013","journal-title":"Haemophilia"},{"issue":"4","key":"2019121211523184300_B2","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1046\/j.1365-2141.1999.01463.x","article-title":"Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized","volume":"105","author":"Astermark","year":"1999","journal-title":"Br J Haematol"},{"issue":"5","key":"2019121211523184300_B3","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/jth.13298","article-title":"When and how to start prophylaxis in boys with severe hemophilia without inhibitors: communication from the SSC of the ISTH","volume":"14","author":"Fischer","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"3","key":"2019121211523184300_B4","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1538-7836.2011.04611.x","article-title":"A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management","volume":"10","author":"Valentino","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"suppl 1","key":"2019121211523184300_B5","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1182\/blood-2018-99-117413","article-title":"Early prophylaxis provides continued joint protection in severe hemophilia A: results of the Joint Outcome Continuation Study [abstract]","volume":"132","author":"Warren","year":"2018","journal-title":"Blood"},{"issue":"6","key":"2019121211523184300_B6","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia","volume":"357","author":"Manco-Johnson","year":"2007","journal-title":"N Engl J Med"},{"issue":"4","key":"2019121211523184300_B7","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/ejh.13108","article-title":"The socioeconomic burden of patients affected by hemophilia with inhibitors","volume":"101","author":"D\u2019Angiolella","year":"2018","journal-title":"Eur J Haematol"},{"issue":"5","key":"2019121211523184300_B8","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/ajh.23957","article-title":"Impact of inhibitors on hemophilia A mortality in the United States","volume":"90","author":"Walsh","year":"2015","journal-title":"Am J Hematol"},{"issue":"23","key":"2019121211523184300_B9","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1182\/blood-2014-07-586347","article-title":"Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A","volume":"124","author":"Calvez","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2019121211523184300_B10","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1056\/NEJMoa1208024","article-title":"Factor VIII products and inhibitor development in severe hemophilia A","volume":"368","author":"Gouw","year":"2013","journal-title":"N Engl J Med"},{"issue":"11","key":"2019121211523184300_B11","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1182\/blood-2006-11-056291","article-title":"Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study","volume":"109","author":"Gouw","year":"2007","journal-title":"Blood"},{"issue":"1","key":"2019121211523184300_B12","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/hae.12246","article-title":"Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors","volume":"20","author":"Antunes","year":"2014","journal-title":"Haemophilia"},{"issue":"6","key":"2019121211523184300_B13","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1182\/blood-2011-08-369132","article-title":"The principal results of the International Immune Tolerance Study: a randomized dose comparison","volume":"119","author":"Hay","year":"2012","journal-title":"Blood"},{"issue":"9","key":"2019121211523184300_B14","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1111\/j.1538-7836.2007.02663.x","article-title":"Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors","volume":"5","author":"Konkle","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"18","key":"2019121211523184300_B15","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1056\/NEJMoa1104435","article-title":"Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors","volume":"365","author":"Leissinger","year":"2011","journal-title":"N Engl J Med"},{"issue":"5","key":"2019121211523184300_B16","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1111\/j.1365-2516.2009.01999.x","article-title":"Paediatric haemophilia with inhibitors: existing management options, treatment gaps and unmet needs","volume":"15","author":"Santagostino","year":"2009","journal-title":"Haemophilia"},{"issue":"2","key":"2019121211523184300_B17","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1046\/j.1365-2516.2003.00840.x","article-title":"Central venous access devices in haemophilia","volume":"10","author":"Valentino","year":"2004","journal-title":"Haemophilia"},{"issue":"2","key":"2019121211523184300_B18","first-page":"189","article-title":"Use of implantable venous access devices in children with severe hemophilia: benefits and burden","volume":"89","author":"Van Dijk","year":"2004","journal-title":"Haematologica"},{"key":"2019121211523184300_B19","unstructured":"Genentech, Inc\n          . Emicizumab. Prescribing information. 2017. https:\/\/www.gene.com\/download\/pdf\/hemlibra_prescribing.pdf. Accessed 4 September 2019."},{"issue":"10","key":"2019121211523184300_B20","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/nm.2942","article-title":"A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model","volume":"18","author":"Kitazawa","year":"2012","journal-title":"Nat Med"},{"key":"2019121211523184300_B21","unstructured":"Roche\n          . Emicizumab. Summary of product characteristics (SmPC). 2018. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/hemlibra-epar-product-information_en.pdf. Accessed 4 September 2019."},{"issue":"9","key":"2019121211523184300_B22","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients with hemophilia A without inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"2019121211523184300_B23","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"2019121211523184300_B24","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/S2352-3026(19)30054-7","article-title":"Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study","volume":"6","author":"Pipe","year":"2019","journal-title":"Lancet Haematol"},{"issue":"4","key":"2019121211523184300_B25","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/j.1365-2516.2006.01292.x","article-title":"The Haemo-QoL Index: developing a short measure for health-related quality of life assessment in children and adolescents with haemophilia","volume":"12","author":"Pollak","year":"2006","journal-title":"Haemophilia"},{"issue":"3","key":"2019121211523184300_B26","doi-asserted-by":"crossref","first-page":"A196","DOI":"10.1016\/j.jval.2013.03.988","article-title":"Development of an inhibitor-specific questionnaire for the assessment of health-related quality of life in haemophilia patients with inhibitors (INHIB-QoL) [abstract]","volume":"16","author":"Von Mackensen","year":"2013","journal-title":"Value Health"},{"issue":"11","key":"2019121211523184300_B27","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1111\/jth.12672","article-title":"Definitions in hemophilia: communication from the SSC of the ISTH","volume":"12","author":"Blanchette","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"suppl 1","key":"2019121211523184300_B28","article-title":"Exposure-response modeling of emicizumab for the prophylaxis of bleeding in haemophilia A patients with and without inhibitors against factor VIII [abstract]","volume":"3","author":"Jonsson","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"issue":"5","key":"2019121211523184300_B29","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1365-2141.2012.09089.x","article-title":"How to manage invasive procedures in children with haemophilia","volume":"157","author":"Ljung","year":"2012","journal-title":"Br J Haematol"},{"issue":"6","key":"2019121211523184300_B30","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.thromres.2012.08.305","article-title":"PRO-PACT: retrospective observational study on the prophylactic use of recombinant factor VIIa in hemophilia patients with inhibitors","volume":"130","author":"Young","year":"2012","journal-title":"Thromb Res"},{"issue":"1","key":"2019121211523184300_B31","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/hae.13353","article-title":"Improved joint health in subjects with severe haemophilia A treated prophylactically with recombinant factor VIII Fc fusion protein","volume":"24","author":"Oldenburg","year":"2018","journal-title":"Haemophilia"},{"issue":"suppl 1","key":"2019121211523184300_B32","first-page":"2368","article-title":"Clinical outcomes of weekly prophylaxis with rFVIIIFc: longitudinal analysis of the A-LONG and ASPIRE study population [abstract]","volume":"130","author":"Shapiro","year":"2017","journal-title":"Blood"},{"issue":"suppl 1","key":"2019121211523184300_B33","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1182\/blood-2018-99-118492","article-title":"Immunogenicity of emicizumab in people with hemophilia A (PwHA): results from the HAVEN 1-4 studies [abstract]","volume":"132","author":"Paz-Priel","year":"2018","journal-title":"Blood"},{"issue":"9","key":"2019121211523184300_B34","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1007\/s40262-017-0616-3","article-title":"A pharmacometric approach to substitute for a conventional dose-finding study in rare diseases: example of phase III dose selection for emicizumab in hemophilia A","volume":"57","author":"Yoneyama","year":"2018","journal-title":"Clin Pharmacokinet"},{"issue":"suppl 1","key":"2019121211523184300_B35","first-page":"S94","article-title":"Model-informed dose selection for pediatric study of emicizumab in hemophilia [abstract]","volume":"103","author":"Yoneyama","year":"2018","journal-title":"Clin Pharmacol Ther"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/134\/24\/2127\/1547419\/bloodbld2019001869.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/134\/24\/2127\/1547419\/bloodbld2019001869.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,12]],"date-time":"2019-12-12T11:52:55Z","timestamp":1576151575000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/134\/24\/2127\/375128\/A-multicenter-openlabel-phase-3-study-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,12]]},"references-count":35,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2019,12,12]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2019001869","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,12]]}}}